Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The capsular polysaccharide of Neisseria meningitidis serogroup W is a complex carbohydrate structure that encapsulates the bacterium, serving as a primary virulence factor by protecting it from host immune defenses such as phagocytosis and complement-mediated lysis (Stephens et al., 2007, The Lancet). Chemically, the serogroup W polysaccharide is composed of repeating units of sialic acid and galactose [→6)-α-D-Galp-(1→4)-α-D-Neup5Ac-(2→] (Harrison et al., 2017, Vaccine). This molecule is the key antigenic component in quadrivalent meningococcal vaccines (MenACWY), where it is often conjugated to a carrier protein like diphtheria toxoid or CRM197 to enhance immunogenicity, particularly in infants (CDC, 2023). By targeting this polysaccharide, vaccines induce the production of serum bactericidal antibodies that provide protective immunity against invasive diseases like meningitis and septicemia (Pollard et al., 2009, Nature Reviews Immunology). Serogroup W has gained prominence due to its association with large-scale outbreaks and high case-fatality rates, emphasizing the importance of this target in global immunization strategies (WHO, 2023). The polysaccharide's structure is distinct from other serogroups, requiring specific inclusion in multi-component vaccines to ensure broad protection against the diverse strains of N. meningitidis (Harrison et al., 2017, Vaccine). Therapeutic interventions primarily focus on preventive immunization, as the polysaccharide itself is not a target for traditional small-molecule drugs but rather for the induction of a targeted immune response (Pollard et al., 2009, Nature Reviews Immunology).
Induction of protective humoral immunity through the production of serogroup-specific bactericidal antibodies that facilitate complement-mediated lysis and opsonophagocytosis of the bacteria (Pollard et al., 2009, Nature Reviews Immunology).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Capsular polysaccharide of Neisseria meningitidis serogroup W (MenW CP) (MenW CP).